Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Long-term data suggests Baxter's Gammagard stabilises Alzheimer's symptoms

This article was originally published in Scrip

Executive Summary

New research suggests that continued use of Baxter's intravenous immunoglobulin (IVIG) product, Gammagard, could help stabilise the symptoms of Alzheimer's disease. Patients in the three-year Phase II extension study were said to suffer no decline in cognition, memory, daily functioning and mood.



Related Companies